There are a number of assistance programs available to help you obtain your medication, if you qualify. To find the program that best meets your needs, we
have created ASSIST, your Access Solutions and Support Team. With one
number to call, you can get answers to your questions about obtaining your medication.
One Number for All Your Product Access Needs: 1-877-UNITHER (1-877-864-8437)
When you call 1-877-UNITHER (1-877-864-8437), your ASSIST Advisor will work to figure out which program is right for you. They can help you resolve issues and manage your case until completion.
ASSIST Is Here to Help
- If you have insurance
You may need assistance in meeting your product co-pay or co-insurance expense. Many people qualify for co-pay assistance. Our ASSIST Advisors can help determine your eligibility.
-
If you’re without insurance
If you qualify, we may be able to help you obtain your medication and supplies if you cannot afford therapy, are not adequately insured, or are close to the lifetime limit of your current insurance policy.*
-
If your insurance is interrupted
If you qualify, we may be able to assist you with continued medication coverage at a reasonable cost or no cost at all, if you experience a temporary interruption of therapy caused by a gap in insurance coverage.*
By calling 1-877-UNITHER (1-877-864-8437), our ASSIST Advisors can also help verify insurance benefits, assist with submissions of prior authorization documentation, provide guidance for pharmacy claim denials and appeals, and more.
Let us ASSIST you with financial solutions and support.
*You must meet certain eligibility criteria to qualify for assistance.
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms
associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic
or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic
indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who
are intolerant of the subcutaneous route, or in whom these risks are considered warranted.
In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical
deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
Important Safety Information for Remodulin
- Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk
of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
- Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH. Remodulin is a potent pulmonary and systemic
vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet
aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. Remodulin dosage adjustment may be
necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care.
Therapy with Remodulin may be used for prolonged periods, and the patient’s ability to administer Remodulin and care for an infusion system should
be carefully considered.
- Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic
effects or for unacceptable infusion site symptoms.
- Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided. Caution
should be used in patients with hepatic or renal insufficiency.
- The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and
infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment
with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising,
and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation, and edema.
For more information about REMODULIN, please see the Full Prescribing Information.
Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).